Press Releases GNI Group Ltd.

Equities

2160

JP3386370005

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-07-05 am EDT			5-day change	1st Jan Change
2,436 ^JPY	+2.40%		+2.83%	-13.92%

Jul. 01	GNI Group Ltd. Announces GYRE Pharmaceuticals Receives Approval from the National Medical Products Administration for Avatrombopag Maleate Tablets	CI
May. 31	Gyre Therapeutics Gets Investigational New Drug Application Approval in China for Pulmonary Arterial Hypertension Therapy	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

GNI : Q&A of Cullgen and Astellas’ Collaboration Agreement	23-06-29	PU
GNI : summary Q&A from Q1 2023 financial results analyst call and other recent inquiries	23-05-23	PU
GNI : FY2023Q1 Earnings Call Transcript	23-05-22	PU
GNI : Amendment of “Q1 FY2023 Financial Results Corporate Presentation” document	23-05-18	PU
GNI : Q1 FY2023 Financial Results Corporate Presentation	23-05-17	PU
GNI : CBIO files 2023Q1 10-Q (quarterly report)	23-05-15	PU
GNI : Consolidated Financial Results for Q1 FY2023(IFRS)	23-05-15	PU
GNI : CBIO submits Form 8-K regarding its Nasdaq listing status	23-05-05	PU
GNI : Monthly Update on the 47th Series Stock Acquisition Rights (Moving Strike Warrants) Exercise Status	23-05-01	PU
GNI : summary Q&A from FY2022 AGM	23-04-11	PU
GNI : First Subject Enrolled for Phase II Clinical Trial of F573 for Injection	23-03-27	PU
GNI : 22nd Annual General Meeting of Shareholders Measures to Prevent the Spread of Covid 19	23-03-16	PU
GNI : Amendment of "FY2022 difference between forecast and actual" document	23-03-07	PU
GNI : Amendment of "FY2022 Financial Results Corporate Presentation" document	23-03-07	PU
GNI : Amendment of "Consolidated Financial Results for FY2022(IFRS)" document	23-03-07	PU
GNI : summary Q&A from full-year 2022 financial results analyst call and other recent inquiries	23-03-02	PU
GNI : Consolidated Financial Results for FY2022(IFRS)	23-02-15	PU
GNI : Monthly Update on the 47th Series Stock Acquisition Rights (Moving Strike Warrants) Exercise Status	23-02-01	PU
GNI : Additional FAQ for Our Disclosure on December 27, 2022, “GNI Group and Catalyst Biosciences Signed Agreements to Advance Liver Fibrosis Drug Development”	23-01-18	PU
GNI : Resuming normal office operations	23-01-13	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases GNI Group Ltd.

Equities

2160

JP3386370005

Press Releases

Filters